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(N = 2000) and a test set (N = 4486). A proportion of glucose
and HbA1c specimens were mismatched by randomly switching
either HbA1c or glucose results. The outcome of interest was
correct classiﬁcation of vials as either ‘matched’ or ‘mismatched’.
The outcome was predicted using a Bayesian network that
encoded probabilistic relationships among analytes, self-reported
diabetes status and a latent ‘mismatch’ variable. Performance
was compared against an established approach LabRespond via
area under the receiver-operating characteristics curves (AUCs).
An AUC = 1.0 and 0.5 represents perfect prediction and random
guessing respectively. RESULTS: The network was predictive of
glucose and HbA1c mismatches that produced 20 mg/dL glucose
and 1 point HbA1c discrepancies between true and mismatched
scores (AUC = 0.84 (+/-0.03)). The network also identiﬁed
errors among those self-reporting diabetes (N = 329) AUC =
0.81 (+/-0.02) and predicted self-report of diabetes diagnosis
AUC = 0.95 (+/-0.01). The network also performed better
(z = 12.04, p < 0.001) than LabRespond (AUC = 0.76 +/- 0.01).
CONCLUSION: A Bayesian network that models probabilistic
relationships among analyte values can accurately identify mis-
matched specimens. The algorithm is best at identifying mis-
matches that result in a clinically signiﬁcant magnitude of error.
Information about diabetes diagnosis acted to reduce uncertainty
in a mismatch. Decision analysis may be have direct application
in reducing cost at point-of-care.
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OBJECTIVE: Human evaluation of laboratory errors is a costly
standard of practice. Automating error detection may reduce
costs and improve patient outcomes. To compare an automated
probabilistic approach (Bayesian network) to human expert
error detection in a pre-diabetic population. METHODS: Two
test sets (A and B) each N = 60 were generated from the results
of the Diabetes Prevention Program (DPP). Glucose values
were randomly drawn from a pre-diabetic distribution and
expected HbA1c score was estimated by the DPP based formula:
HbA1c = 4.22 + 0.1604 ¥ Glucose. In each test set, 37% of the
HbA1c scores were mismatched to generate vial labeling errors.
Eleven experts recruited from the American Academy of Clinical
Chemists and a Bayesian network evaluated the results to detect
mismatched vials. Six and ﬁve experts were assigned to test sets
A and B respectively. Receiver-Operating Characteristics (ROC)
curves were generated for each expert and for the Bayesian
network and area under the curves (AUCs) were compared via
null hypothesis testing. An AUC = 1 and 0.5 represents perfect
prediction and random guessing respectively. RESULTS: The
Bayesian network was predictive of glucose and HbA1c mis-
matches in both Test Set A (AUC = 0.86 (+/-0.05)) and Test Set
B (AUC = 0.93 (+/-0.04)). Expert performance was on average
worse in Test Sets A (AUC = 0.74 (+/-0.07)) and B (AUC = 0.76
(+/-0.07)). Individual analysis revealed that the network per-
formed signiﬁcantly better (z < 1.96, p < 0.05) than 7 of the 11
experts; in no case did the network perform worse than the
experts. CONCLUSION: A Bayesian network that models
probabilistic relationships among analyte values is often better
than laboratory experts at identifying laboratory errors. This
suggests that an automated program may help reduce costs and
improve patient outcomes in the laboratory.
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OBJECTIVE: Fibrin sealants are efﬁcacious in reducing peri-
operative bleeding during a variety of surgical procedures, which
may result in decreased hospital costs and lengths of stay (LOS).
This study sought to compare hospital costs and LOS by three
ﬁbrin sealants used in cardiac surgical procedures. METHODS:
Data were extracted from a large U.S. hospital-based, service-
level comparative database. Procedures were identiﬁed using
principal ICD-9 codes. Patients who received either FloSeal®
only or one of two comparison products (Gelfoam® + thrombin
or Surgicel® + thrombin) and were discharged from hospital
between April 1, 2003 and September 30, 2006 were included.
Costs were considered from the hospital perspective and were
derived from either reported actual costs or an estimated
calculation of costs-to-charges from the Medicare Cost Report.
Regression modeling with log transformation was employed to
compare differences in ﬁxed hospital costs (those insensitive to
volume), variable costs (those sensitive to volume), and post-
operative LOS. Control variables included age, gender, All
Patient Reﬁned-Diagnosis Related Group severity codes, region,
hospital teaching status, bed size, population served (urban
or rural), and primary payer. RESULTS: A total of 35,672
discharges were included. The regression models showed that
patients who received Gelfoam + thrombin had higher ﬁxed and
variable costs (+21% and +40%, p < 0.01, respectively) and
Surgicel + thrombin had higher ﬁxed and variable costs (+18%
and +14.5%, p < 0.01, respectively) compared to FloSeal. In
terms of ﬁxed costs, this amounted to an additional $21,803 for
Gelfoam + thrombin and an additional $19,208 for Surgicel +
thrombin cohorts. In variable costs, this amounted to an
additional $26,609 for Gelfoam + thrombin and $22,181 for
Surgicel + thrombin cohorts. All three cohorts had similar post-
operative LOS. CONCLUSION: FloSeal demonstrated cost
reduction in hospital stays for cardiac procedures, compared
to two other ﬁbrin sealants. Given small margins achieved by
hospitals today, cost-effective surgical aids with better or similar
outcomes should be considered in surgical service lines.
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OBJECTIVE: Fibrin sealants are used in a variety of surgical
procedures to reduce wound bleeding. This may consequently
decrease hospital costs and lengths of stay (LOS). This study
sought to compare costs and LOS following ﬁbrin sealant use
during spinal surgery. METHODS: Data were extracted from a
largeU.S. hospital-based, service-level comparative database. Pro-
cedures were identiﬁed using principal ICD-9 codes. Patients who
received either FloSeal® only or one of two comparison products
(Gelfoam® + thrombin or Surgicel® + thrombin) and were dis-
charged from hospital between April 1, 2003 and September 30,
2006 were included. Costs were considered from the hospital
perspective and were derived from either reported actual costs or
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an estimated calculation of costs-to-charges from the Medicare
Cost Report. Regression modeling with log transformation was
employed to compare differences in ﬁxed hospital costs (those
insensitive to volume), variable costs (those sensitive to volume),
and post-operative LOS. Control variables included age, gender,
All Patient Reﬁned-Diagnosis Related Group severity codes,
region, hospital teaching status, bed size, population served
(urban or rural), and primary payer. RESULTS: A total of 82,788
discharges were included. The models demonstrated that patients
who received Gelfoam + thrombin had higher ﬁxed and variable
costs (+6.1% and +7.3%, respectively, p < 0.01) and Surgicel +
thrombin patients had higher ﬁxed and variable costs (+18% and
+10%, p < 0.01, respectively) compared to FloSeal only. In terms
of ﬁxed costs, the predicted increase was $15,956 for Gelfoam +
thrombin and $18,639 for Surgicel + thrombin patients. In
terms of variable costs, the predicted increase was $25,413
per Gelfoam + thrombin and $24,909 per Surgicel + thrombin
patient. Surgicel+ thrombin patients also had higher (+6%,
p < 0.01) post-operative LOS compared to FloSeal patients.
CONCLUSION: FloSeal demonstrated signiﬁcant cost reductions
and post-operative LOS, compared to other commonly-used
products. Limited prospective reimbursements based on a DRG
system make it necessary for health care providers to consider
more cost-effective surgical aids for spinal surgeries.
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OBJECTIVE: We assessed the cost-effectiveness of dental
implant 1st line strategy versus ﬁxed partial denture (and
denture) in patients suffering from one single missing tooth.
METHODS: The model used a simulation decision framework
over a 20-year period. Potential treatment switches can occur
every 5 years. Transition probabilities came from literature,
epidemiological reports or expert opinions. They have been
programmed using speciﬁc distribution ranges to simulate the
patients and practice variability, and to take into account param-
eters uncertainty. Direct medical costs have been assessed accord-
ing to a speciﬁc cost survey in France. Probabilistic sensitivity
analyses were conducted using 5000 Monte-Carlo simulations
generating conﬁdence intervals of model outcomes. RESULTS:
The cost distribution indicates a peak at €3000 for the bridge
strategy. The distribution for the implant strategy is more ﬂat,
showing the maximum ranging from €2500 to €3500. The model
simulations establish that total mean cost of the bridge 1st line
strategy is €4385 per patient over 20 years (minimum: €1850;
maximum: €17,267), providing 69% of success rate. Total mean
cost of the implant 1st line strategy is €3517 per patient over 20
years (minimum: €1990 Euros; maximum: €10,221 Euros), with
92% of success rate. Differences are statistically signiﬁcant for
both total mean costs (p < 0.001) and success rate (p < 0.001).
The mean cost-effectiveness (cost per functional dental unit in
position) is shown in Figure 3c. It indicates that the bridge
strategy is signiﬁcantly higher (p < 0.001) than the implant strat-
egy with €6286/success versus 3819 Euros/success respectively.
CONCLUSION: This simulation modeling approach is the very
ﬁrst robust model in the ﬁeld of implantology. Implant as the 1st
line strategy appears to be the “dominant” strategy, considering
the lower overall costs and the higher success rate.
PHC4
COST-EFFECTIVENESS ANALYSIS OF
THROMBOPROPHYLACTIC STRATEGIES OVER 1YEAR AFTER
TOTAL HIP REPLACEMENT INVETERAN PATIENTS
Raisch DW1, Campbell HM1, Khan N2,Taylor Z1, Becker T1
1Department of Veterans Affairs Cooperative Studies Program,
Albuquerque, NM, USA, 2University of New Mexico, Albuquerque,
NM, USA
OBJECTIVE: For 20 years, thromboprophylactic strategies (TSs)
have been used after total hip replacement (THR). Our objective
was to conduct a comprehensive cost effectiveness analysis (CEA)
of TSs for THR from the health payer perspective. METHODS:
We extracted national data for Veteran patients receiving THR,
including 1-year follow-up of all heath care utilization and
complications of venous thromboembolic events (VTE: deep vein
thrombosis, pulmonary embolism), thombocytopenia, bleeding,
and death. Diagnostic codes were used to identify most compli-
cations. A comparative CE model, incorporating fondaparinux,
was developed. Incremental cost-effectiveness ratios (ICERs)
were calculated to compare TSs. Life-years gained (LYG) were
calculated using actuarial tables for life expectancy. Since fonda-
parinux was rarely used in the VA, we applied rates from pub-
lished trials and used our data to estimate proportional increases
in complication rates for fondaparinux from day 50 through one
year. We applied VA costs. Fondaparinux costs were based upon
mean costs of outcomes of the other TSs. One-way sensitivity
analyses (SA) were performed by incorporating the mean prob-
abilities of DVT in the other TSs into the least-costly TS or
decreasing the costs of complication arms by one standard devia-
tion in all but the least-costly TS. RESULTS: There were 1722
patients, 90 VTEs, and 48 deaths. Dalteparin was dominant;
the least-costly per patient with fewest VTEs ($18,850, 2.4%)
compared to warfarin ($18,953, 6.4%), enoxaparin ($19,965,
2.7%), enoxaparin/warfarin ($24,809, 21.6%), and fonda-
parinux ($20,759, 5.2%). Thus, ICERS indicated more costs and
more events with other TSs. Deaths occurred in 2.4% of dalte-
parin patients versus 2.3% for enoxaparin and, estimated, 1.0%,
for fondaparinux, thus ICERS for LYG were $35,754/LYG and
$6381/LYG, respectively. Dalteparin and other treatments were
dominant over warfarin (2.9% deaths) and enoxaparin/warfarin
(6.0% deaths)for LYG. Each SA showed dalteparin remained the
least-costly TS per VTE avoided. CONCLUSION: Dalteparin
was slightly more effective and less costly.
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OBJECTIVE: There is a lack of cost effectiveness (CE) analyses
of thromboprophylactic strategies (TSs) for total knee replace-
ment (TKR) that incorporate outpatient care, long-term follow-
up, or complications besides venothrombotic events (VTE: deep
vein thrombosis, pulmonary embolism). The objective was to
assess the CE of TSs for TKR from the health payer perspective
including complications of VTE, hemorrhage, thrombocyto-
penia, and death. METHODS: We searched national Veterans
Affairs (VA) datasets for all health care use, outcomes and VA
costs for patients receiving TKR within one year. Our follow-up
was one year. Diagnostic codes were used to identify complica-
tions. Life-years gained (LYG) were calculated using actuarial
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